Mon premier blog

Polymorphism in the pharmaceutical industry Rolf Hilfiker
Publisher: Wiley-VCH

€�Omixon has “Thus, pharmaceutical companies can shorten the time to approval and reduce the risk of late-stage failures. Validates and extends previous findings. Avoiding action has not yet widely been taken on polymorphism by the global pharmaceutical industry, so it is worth repeating the story. Similarly, polymorphisms of transporters . Variations in drug response due to polymorphism of receptors can be illustrated with β2 adrenergic receptor polymorphisms, where homozygous mutants with decreased expression of β2 adrenergic receptors do not have a predictable response to the use of drugs like salbutamol in asthma. Pharmacogenomics in clinical trials is a relatively new area in which considerable hesitation is shown by pharmaceutical companies. What is perhaps more exciting, he says, is that “incrementally, this strengthens the evidence that a relatively uncommon polymorphism that lowers LDL substantially through PSCK9 mechanisms translates into differences in IHD.” The pharmaceutical industry is currently looking at PSCK9 inhibition as a target for cardiovascular disease, “and these data certainly support that effort,” he maintains. Thermodynamics versus Kinetics and the Formation of Polymorphs. Methods of Polymorph Characterization. Despite its value, accurate and robust analysis of HLA genes has not been possible due to technical challenges related to repeated segments and pseudogenes significantly longer than the typical NGS read length of 150 to 250nt, a combination of extremely polymorphic exons and conserved regions, a haplotype structure, and phasing issues. Case Studies from the Pharmaceutical Industry. Thermodynamics of Polymorphism.